Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DM65KL8)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Bestasone; Biscosal; Cortalar; Fluocinolide; Fluocinonido; Fluocinonidum; Fluonex; Fluzon; Lidex; Lonide; Lyderm;Metosyn; Straderm; Topsymin; Topsyn; Vanos; Fluocinolide acetate; Fluocinolone acetonide acetate; Fluocinonide Emulsified Base; Fluocinonide FAPG; Lidex E; Synalar acetate; Fluocinolone acetonide 21-acetate; Fluocinonido [INN-Spanish]; Fluocinonidum [INN-Latin]; Fluonex (TN); LIDEX (TN); LIDEX-E; Lidex (TN); Lonide (TN); Lyderm (TN); Vanos (TN); Lidex-E (TN); Fluocinonide (JP15/USP/INN); Fluocinonide [USAN:BAN:INN:JAN]; Fluocinonide [USAN:INN:BAN:JAN]; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate (8CI); Pregna-1,4-diene-3,20-dione, 6-alpha, 9-difluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic17-acetal with acetone, 21-acetate; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone, 21-acetate
| |||||
| Therapeutic Class | Antiinflammatory Agents | |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Kidney
Normal (Immortalized)
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
